Salvat’s new BONECURE project is an innovative medical advancement based on pre-differentiated mesenchymal cells designed to treat patients with bone consolidation problems post-fracture (atrophic pseudoarthrosis). A Phase II clinical trial is being completed with promising results in terms of both efficacy and safety, in patients with long bone pseudoarthrosis. Salvat has conducted this project in […]
Salvat’s News and Press kit
Salvat at a glance
What are we doing right now
A new automated robotic line costing more than €6 million has enabled Cristalmina to increase production from 2.5 million to 15 million units per year By 2021, the company plans to have authorisation to market Cristalmina in more than 26 European countries, which will be followed by Asia and the USA in the years to […]
Again this year, Laboratorios Salvat, S.A. has been granted with the rating “VERY GOOD” by the PROFARMA 2019 program of the Spanish Ministry of Industry, which values pharmaceutical companies based on their excellence in Industrial, economic and Research, Development and Innovation activities. This qualification represents an important recognition of Salvat’s continued efforts towards its objective […]
The research, currently underway both in the United States of America and Europe, will involve an investment of more than $10 million. The worldwide launch of the new medicament to treat this type of external otitis, expected for the end of 2021, reinforces Salvat’s positioning in otology at an international level. The company’s international business […]
Japanese companies from the pharmaceutical sector visit Pharmaloop’s facilities (a Salvat company) through @ICEX and @IcexJapon.